Sarepta has received US FDA approval for updated prescribing information for Elevidys, an AAV-based gene transfer therapy.

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

The MarketWatch News Department was not involved in the creation of this content.-- Expanded Dyno Frontiers Program connects therapeutic developers to a marketplace of partners re ...

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...

Quality, stability, sustainability, and the increased and thoughtful integration of artificial intelligence are foremost in the minds of those on the leading edge of testing trends.

With a recent breakthrough in genetic technology, producers can expect to achieve the same embryo numbers from half the ...

The global TCR therapy market size is calculated at USD 410.6 million in 2025 and is expected to reach around USD 1264.73 million by 2034, growing at a CAGR of 13.44% for the forecasted period.Ottawa, ...

Anixa Biosciences (ANIX) announced that the International Nonproprietary Names, or INN, Expert Committee of the World Health Organization, or WHO, ...

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the ...

The UAE is set to become a global hub for fertility care and medical tourism, driven by government support, technological ...

With the recent news of Tom Brady cloning his dog, the spotlight is once again on the surging popularity of pet cloning ...